Elsevier

Experimental Gerontology

Volume 33, Issue 5, August 1998, Pages 371-378
Experimental Gerontology

Original Articles
The importance of inflammatory mechanisms in alzheimer disease

https://doi.org/10.1016/S0531-5565(98)00013-8Get rights and content

Abstract

Lesions in such chronic neurodegenerative disorders as Alzheimer disease (AD), Parkinson disease, the parkinsonism dementia complex of Guam, and amyotrophic lateral sclerosis have associated with them a variety of proteins known to be involved in inflammatory processes. This is particularly true of AD, where inflammatory reactions are thought to be important contributors to the neuronal loss. Proteins present include complement proteins, complement inhibitors, acute phase reactants, inflammatory cytokines, proteases, and protease inhibitors. Studies of cultured human astrocytes and microglia, obtained from postmortem brain, have established that nearly all of these proteins are produced by one or another of these cell types. Human neurons also produce many inflammatory proteins and their inhibitors, creating complex interactions. Accumulations of amyloid and extracellular tangles apparently act as irritants, causing the activation of complement, the initiation of reactive changes in microglia, and the release of potentially neurotoxic products. Such products include the membrane attack complex, oxygen free radicals, and excess glutamate. Twenty epidemiological studies that have been published to date indicate that populations taking antiinflammatory drugs have a significantly reduced prevalence of AD or a slower mental decline. One small clinical trial with indomethacin showed arrest of the disease over a six-month period. Therapeutic intervention in key inflammatory processes holds great promise for the amelioration of AD and possibly other neurodegenerative disorders.

Section snippets

Acknowledgements

Our research on Alzheimer disease is supported by grants from the Alzheimer Society of B.C., the Jack Brown and Family A.D. Research Fund, and donations from individual British Columbians.

References (22)

  • M.I. Jenkinson et al.

    Rheumatoid arthritis and senile dementia of the Alzheimer’s type

    Br. J. Rheumatol.

    (1989)
  • Cited by (311)

    • Metformin in Alzheimer's disease: An overview of potential mechanisms, preclinical and clinical findings

      2022, Biochemical Pharmacology
      Citation Excerpt :

      Generally, according to the mentioned studies, the effect of metformin on tau phosphorylation is controversial and more studies are needed to clarify the accurate effect of metformin on this process. One of the main characteristic pathological features of AD is neuroinflammation [69]. Initially, the use of NSAID drugs was recognized as reducing the risk of AD by 50% [70], and finally, their protective effects against Aβ-induced neurotoxicity were proven in various culture and animal models [71,72].

    • C-reactive protein and risk of Alzheimer's disease

      2022, Neurobiology of Aging
      Citation Excerpt :

      CRP can activate the classic complement system, causing cell lysis and phagocytosis of cell fragments (McGeer and McGeer, 1998). For AD, activation of complement system could not only ruin damaged neurons, but also lead to bystander lysis of healthy cells (McGeer and McGeer, 1998). Moreover, activators of the complement pathway such as CRP, had also been observed in AD lesions (Yasojima et al., 2000).

    View all citing articles on Scopus
    View full text